{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T23:20:01Z","timestamp":1795216801916,"version":"4.10.3"},"reference-count":33,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune dysregulation, immunosuppressive therapy and active inflammatory bowel disease (IBD) increase susceptibility to respiratory syncytial virus (RSV) infection. We evaluated the risk of RSV infection in patients with active and nonactive IBD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using the TriNetX Analytics Network from October 2024 through March 2025, we identified adult patients (aged \u226518\u2009years) with IBD. Patients were classified as having active IBD if they had recent IBD complications, IBD-related surgery, or elevated inflammatory markers (within preceding 6\u2009months); those without recent complications,surgeries, or elevated inflammatory markers were classified as having nonactive IBD within the same period. Outcomes were assessed within 180\u2009days after the index date and included RSV infection, bacterial pneumonia, intensive care unit (ICU) admission, and mechanical ventilation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 141\u200a763 patients (47\u200a883 patients with active IBD, 93\u200a880 patients with nonactive IBD), 2879 patients with active IBD and 3583 with nonactive IBD received the RSV vaccination. After matching, each cohort included 46\u200a308 patients. Active IBD was associated with higher odds of RSV infection (adjusted odds ratio [aOR], 1.55; 95% CI, 1.18-2.04), bacterial pneumonia (aOR, 2.58; 95% CI, 2.08-3.19), ICU admissions (aOR, 2.07; 95% CI, 1.88-2.28), and mechanical ventilation (aOR, 2.41; 95% CI, 2.01-2.88). RSV risk remained higher among patients with active IBD both with and without systemic corticosteroid exposure. Among RSV-vaccinated patients, RSV infection rates were not significantly different between active and nonactive IBD (aOR, 1.26; 95% CI, 0.78-1.79).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with active IBD had higher risk of RSV infection. Increased RSV risk was observed both among patients with active IBD with and without systemic corticosteroid exposure. Among RSV-vaccinated patients, RSV infection rates were not significantly different between active and nonactive IBD. Further prospective studies are needed to validate these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izag134","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:01:14Z","timestamp":1784739674000},"source":"Crossref","is-referenced-by-count":1,"title":["Increased risk of respiratory syncytial virus infection in patients with active inflammatory bowel disease: a matched cohort study"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6662-5883","authenticated-orcid":false,"given":"Mohamed H","family":"Eldesouki","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, New York Medical College at Saint Michael\u2019s Medical Center , Newark, NJ 07102,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Hafez","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Saint Louis University School of Medicine , St. Louis, MO 63104,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed E","family":"Salem","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic Florida , Weston, FL 33331,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Alomari","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Arkansas for Medical Sciences , Little Rock, AR 72205,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana G","family":"Hashash","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic , Jacksonville, FL 32224,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6371-2441","authenticated-orcid":false,"given":"Francis A","family":"Farraye","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic , Jacksonville, FL 32224,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"2026072213010880500_izag134-B1","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S2213-2600(24)00255-8","article-title":"Respiratory syncytial virus infections in adults: a narrative review","volume":"12","author":"Wildenbeest","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026072213010880500_izag134-B2","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1001\/jamainternmed.2024.0212","article-title":"Acute cardiac events in hospitalized older adults with respiratory syncytial virus infection","volume":"184","author":"Woodruff","year":"2024","journal-title":"JAMA Intern Med"},{"key":"2026072213010880500_izag134-B3","doi-asserted-by":"publisher","first-page":"e2444756","DOI":"10.1001\/jamanetworkopen.2024.44756","article-title":"Burden of respiratory syncytial virus\u2013associated hospitalizations in US adults, October 2016 to September 2023","volume":"7","author":"Havers","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026072213010880500_izag134-B4","first-page":"267","article-title":"Incidence of respiratory syncytial virus\u2013associated hospitalization among adults in Ontario, Canada, 2017-2019","volume":"231","author":"Buchan","year":"2025","journal-title":"J Infect Dis"},{"key":"2026072213010880500_izag134-B5","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.15585\/mmwr.mm7240a1","article-title":"Characteristics and outcomes among adults aged \u226560 years hospitalized with laboratory-confirmed respiratory syncytial virus\u2014RSV-NET, 12 States","volume":"72","author":"Havers","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026072213010880500_izag134-B6","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S0140-6736(24)01738-0","article-title":"Effectiveness of respiratory syncytial virus vaccines against medically attended RSV-associated illness among adults in the United States","volume":"404","author":"Payne","year":"2024","journal-title":"Lancet"},{"key":"2026072213010880500_izag134-B7","first-page":"738","article-title":"Canadian Association of Gastroenterology Clinical Practice Guideline for immunizations in patients with inflammatory bowel disease\u2014Part 2: inactivated vaccines","volume":"160","author":"Jones","year":"2021","journal-title":"Gastroenterology"},{"key":"2026072213010880500_izag134-B8","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.14309\/ajg.0000000000003541","article-title":"ACG Clinical Guideline Update: preventive care in inflammatory bowel disease","volume":"120","author":"Farraye","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"2026072213010880500_izag134-B9","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.cgh.2024.12.011","article-title":"AGA Clinical Practice Update on noncolorectal cancer screening and vaccinations in patients with inflammatory bowel disease: expert review","volume":"23","author":"Caldera","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026072213010880500_izag134-B10","doi-asserted-by":"publisher","first-page":"e735","DOI":"10.1016\/S2665-9913(21)00247-2","article-title":"COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses","volume":"3","author":"Fagni","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2026072213010880500_izag134-B11","doi-asserted-by":"publisher","first-page":"933774","DOI":"10.3389\/fimmu.2022.933774","article-title":"Risks of SARS-CoV-2 infection and immune response to COVID-19 vaccines in patients with inflammatory bowel disease: current evidence","volume":"13","author":"Esposito","year":"2022","journal-title":"Front Immunol"},{"key":"2026072213010880500_izag134-B12","doi-asserted-by":"publisher","first-page":"102661","DOI":"10.1016\/j.coi.2025.102661","article-title":"COVID-19 and inflammatory bowel disease: what to know","volume":"97","author":"Godat","year":"2025","journal-title":"Curr Opin Immunol"},{"key":"2026072213010880500_izag134-B13","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1053\/j.gastro.2020.04.012","article-title":"AGA Clinical Practice Update on management of inflammatory bowel disease during the COVID-19 pandemic: expert commentary","volume":"159","author":"Rubin","year":"2020","journal-title":"Gastroenterology"},{"key":"2026072213010880500_izag134-B14","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/MOG.0000000000000741","article-title":"Optimal inflammatory bowel disease management during the global coronavirus disease 2019 pandemic","volume":"37","author":"El Ouali","year":"2021","journal-title":"Curr Opin Gastroenterol"},{"key":"2026072213010880500_izag134-B15","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1136\/gutjnl-2021-326784","article-title":"Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic","volume":"71","author":"Lin","year":"2022","journal-title":"Gut"},{"key":"2026072213010880500_izag134-B16","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.14309\/ajg.0000000000002682","article-title":"Patients with inflammatory bowel disease are at increased risk of hospitalization due to respiratory syncytial virus","volume":"119","author":"Smith","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2026072213010880500_izag134-B17","doi-asserted-by":"publisher","first-page":"5874","DOI":"10.3390\/jcm12196419","article-title":"Lung involvement in inflammatory bowel diseases: shared pathways and unwanted connections","volume":"12","author":"Cavalli","year":"2023","journal-title":"J Clin Med"},{"key":"2026072213010880500_izag134-B18","doi-asserted-by":"publisher","first-page":"8912","DOI":"10.3390\/ijms26188912","article-title":"From gut to lungs: the hidden respiratory impacts of inflammatory bowel disease\u2014a systematic review of the literature","volume":"26","author":"Preotesoiu","year":"2025","journal-title":"IJMS"},{"key":"2026072213010880500_izag134-B19","first-page":"6403","article-title":"Investigation of the relationships among respiratory syncytial virus infection, T-cell immune response, and intestinal flora","volume":"27","author":"Zheng","year":"2023","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2026072213010880500_izag134-B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21037\/atm-25-141","article-title":"Impact of tobacco use on inpatient outcomes in inflammatory bowel disease: a retrospective matched cohort study","volume":"14","author":"Eldesouki","year":"2026","journal-title":"Ann Transl Med"},{"key":"2026072213010880500_izag134-B21","doi-asserted-by":"publisher","first-page":"e00840","DOI":"10.14309\/ctg.0000000000000840","article-title":"Patients with inflammatory bowel disease are at increased risk of respiratory syncytial virus infections after severe acute respiratory syndrome coronavirus 2 infection: a propensity-matched cohort analysis","volume":"16","author":"Alsakarneh","year":"2025","journal-title":"Clin Transl Gastroenterol"},{"key":"2026072213010880500_izag134-B22","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-026-09773-1","article-title":"Severe influenza-related outcomes in patients with inflammatory bowel disease on immunosuppressive therapy: a propensity-matched cohort analysis","author":"Eldesouki","year":"2026","journal-title":"Dig Dis Sci"},{"key":"2026072213010880500_izag134-B23","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1111\/apt.18275","article-title":"A nationwide cohort study of inflammatory bowel disease, histological activity, and fracture risk","volume":"60","author":"M\u00e5rild","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2026072213010880500_izag134-B24","doi-asserted-by":"publisher","first-page":"101722","DOI":"10.1016\/j.eclinm.2022.101722","article-title":"Histological remission in inflammatory bowel disease and risk of adverse pregnancy outcomes: a nationwide study","volume":"53","author":"M\u00e5rild","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2026072213010880500_izag134-B25","first-page":"e187","article-title":"Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents","volume":"22","author":"Perico","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"suppl 1","key":"2026072213010880500_izag134-B26","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1038\/ajg.2011.58","article-title":"An evidence-based systematic review on medical therapies for inflammatory bowel disease","volume":"106","author":"Talley","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2026072213010880500_izag134-B27","first-page":"327","article-title":"Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies","volume":"9","author":"Brattsand","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"2026072213010880500_izag134-B28","doi-asserted-by":"publisher","first-page":"691480","DOI":"10.3389\/fimmu.2021.691480","article-title":"Glucocorticoid therapy in inflammatory bowel disease: mechanisms and clinical practice","volume":"12","author":"Bruscoli","year":"2021","journal-title":"Front Immunol"},{"key":"2026072213010880500_izag134-B29","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/MCG.0000000000000758","article-title":"Corticosteroids and thiopurines, but not tumor necrosis factor antagonists, are associated with cytomegalovirus reactivation in inflammatory bowel disease: a systematic review and meta-analysis","volume":"51","author":"Shukla","year":"2017","journal-title":"J Clin Gastroenterol"},{"key":"2026072213010880500_izag134-B30","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3390\/cells14201589","article-title":"From cytokines to biomarkers: mapping the immunopathology of inflammatory bowel disease","volume":"14","author":"Baum","year":"2025","journal-title":"Cells"},{"key":"2026072213010880500_izag134-B31","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/ecco-jcc\/jjy047","article-title":"Respiratory tract infections in patients with inflammatory bowel disease: safety analyses from vedolizumab clinical trials","volume":"12","author":"Feagan","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2026072213010880500_izag134-B32","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/ecco-jcc\/jjac141","article-title":"Tofacitinib for the treatment of ulcerative colitis: an integrated summary of up to 7.8 years of safety data from the global clinical programme","volume":"17","author":"Sandborn","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026072213010880500_izag134-B33","doi-asserted-by":"publisher","first-page":"696","DOI":"10.15585\/mmwr.mm7332e1","article-title":"Use of respiratory syncytial virus vaccines in adults aged \u226560 years: updated recommendations of the advisory committee on immunization practices\u2014United States, 2024","volume":"73","author":"Britton","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izag134\/69799301\/izag134.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izag134\/69799301\/izag134.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:01:15Z","timestamp":1784739675000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article\/doi\/10.1093\/ibd\/izag134\/8739925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":33,"URL":"https:\/\/doi.org\/10.1093\/ibd\/izag134","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"izag134"}}